NEWS AND UPDATES
March 2025
Galibra Neuroscience was invited to participate in the Investival Showcase USA Event at Miami, March 10-11.
December 2024
Galibra Neuroscience presented updates in the SLC6A1 and CURE GABA-A Scientific Meetings at Los Angeles.
Dr Henry Lee presented in the Future Benchmarks of Epilepsy Care session and latest work on SSADH at the Annual Meeting of American Epilepsy Society.
Dr Henry Lee was named one of the Young Investigators of the Rare Epilepsy Network 2024.
Rare Documentary featuring our own Amber was premiered at Harvard Medical School
September 2024
Construction of an inducible GABA-T mouse model has begun.
July 2024
Dr Henry Lee discussed the key elements of developing gene therapies for inherited disorders of neurotransmission including SSADH deficiency in a podcast at JIMD.
May 2024
Dr Henry Lee presented our work on SSADH deficiency in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
Galibra Neuroscience obtained Option License Agreement from Boston Children’s Hospital for developing AAV-mediated gene supplement therapy for SLC6A1-related disorders.
April 2024
Dr Guangping Gao joined Galibra Neuroscience as AAV Manufacturing Consultant.
Brad Hoffman joined Galibra Neuroscience as Director of Business Development.
January 2024
Galibra Neuroscience received its first funding support from an angel investor.
December 2023
Our work on SSADH deficiency was featured in a poster highlight session in the American Epilepsy Society Annual Meeting.
Amber Freed joined Galibra Neuroscience as Chief Development Officer.
Galibra Neuroscience obtained Option License Agreement from Boston Children’s Hospital for developing AAV-mediated gene replacement therapy for SSADH deficiency.
Dr Phillip Pearl joined Galibra Neuroscience as Clinical Study Consultant.
2023
Galibra Neuroscience was founded by Drs Alexander Rotenberg and Henry Lee.
